TWI488628B - 水楊酸藥物之組合物及裝置 - Google Patents
水楊酸藥物之組合物及裝置 Download PDFInfo
- Publication number
- TWI488628B TWI488628B TW099134249A TW99134249A TWI488628B TW I488628 B TWI488628 B TW I488628B TW 099134249 A TW099134249 A TW 099134249A TW 99134249 A TW99134249 A TW 99134249A TW I488628 B TWI488628 B TW I488628B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- dispenser
- salicylic acid
- film
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 131
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title claims description 67
- 229960004889 salicylic acid Drugs 0.000 title claims description 34
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 title claims description 33
- 239000003814 drug Substances 0.000 title claims 2
- 229940079593 drug Drugs 0.000 title 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229920001220 nitrocellulos Polymers 0.000 claims description 14
- 239000000020 Nitrocellulose Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 230000007246 mechanism Effects 0.000 claims description 11
- 230000004888 barrier function Effects 0.000 claims description 10
- 206010036790 Productive cough Diseases 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 8
- 208000024794 sputum Diseases 0.000 claims description 8
- 210000003802 sputum Anatomy 0.000 claims description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 235000005822 corn Nutrition 0.000 claims description 5
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 5
- 208000003643 Callosities Diseases 0.000 claims description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- 241000723346 Cinnamomum camphora Species 0.000 claims description 3
- 229930008380 camphor Natural products 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- 229940116333 ethyl lactate Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 229960000846 camphor Drugs 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 53
- 239000000499 gel Substances 0.000 description 25
- 210000003491 skin Anatomy 0.000 description 25
- 239000002904 solvent Substances 0.000 description 18
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 13
- 210000000282 nail Anatomy 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 11
- 239000002537 cosmetic Substances 0.000 description 11
- 238000009835 boiling Methods 0.000 description 10
- 239000003410 keratolytic agent Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 210000004906 toe nail Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000565 sealant Substances 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- QCZAWDGAVJMPTA-RNFRBKRXSA-N ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C Chemical compound ClC1=CC=CC(=N1)C1=NC(=NC(=N1)N[C@@H](C(F)(F)F)C)N[C@@H](C(F)(F)F)C QCZAWDGAVJMPTA-RNFRBKRXSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229960000953 salsalate Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- -1 mouth cleaners Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- VVMKVFQYONGBPV-MKWAYWHRSA-N (z)-4-butoxy-4-oxobut-2-enoic acid;methoxyethene Chemical compound COC=C.CCCCOC(=O)\C=C/C(O)=O VVMKVFQYONGBPV-MKWAYWHRSA-N 0.000 description 1
- UVHQXWILFGUDTA-LNKPDPKZSA-N (z)-4-ethoxy-4-oxobut-2-enoic acid;methoxyethene Chemical compound COC=C.CCOC(=O)\C=C/C(O)=O UVHQXWILFGUDTA-LNKPDPKZSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- LODHFNUFVRVKTH-ZHACJKMWSA-N 2-hydroxy-n'-[(e)-3-phenylprop-2-enoyl]benzohydrazide Chemical compound OC1=CC=CC=C1C(=O)NNC(=O)\C=C\C1=CC=CC=C1 LODHFNUFVRVKTH-ZHACJKMWSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 240000005295 Nyssa aquatica Species 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 239000010103 Podophyllin Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229960000411 camphor oil Drugs 0.000 description 1
- 239000010624 camphor oil Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940052296 esters of benzoic acid for local anesthesia Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000003699 hair surface Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940068582 podophyllin Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000008377 tooth whitener Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Description
本申請案主張2009年10月8日申請之美國臨時申請案第61/249,788號之優先權。該申請案之全文以引用的方式併入本文中。
最近已發展週期性藥劑分配傳送系統,以提供化妝品及醫藥產品之單位劑型傳送。此等系統係經設計成易於操控,從而分配及施用該醫藥產品。此等系統包括諸如美國專利第7,309,185號及美國公開申請案第2007/0020038號中所述之筆型分配器之裝置,其據稱可將化妝品及醫藥產品儲存於一亦包含用於施用產品之整合設備之裝置中。此等裝置據稱可用於各種化妝品或醫藥產品,其包括潔齒劑,諸如牙膠、牙膏、漱口液、口腔清洗劑、牙齒增白劑、化妝品諸如睫毛膏及眼線筆、護髮產品及/或皮膚治療組合物。
在此以前從未以該等系統製成該傳送系統可利用之包括易揮發性溶劑之某些局部醫藥/化妝品組合物。特定言之,此等裝置可用於局部液體化妝品或醫藥組合物,但該組合物必需包含作為活性成分及其他試劑之傳送載劑之大量揮發性溶劑,諸如薄膜形成劑。例如,美國專利第5,433,950號闡述治療皮膚損傷之某些液體及凝膠調配物,該調配物包含可撓性火棉膠載劑,其包括在主要為二乙醚之揮發性溶劑中之硝化纖維薄膜形成劑。該組合物可包含用於治療諸如疣、胼胝、雞眼之皮膚疾病,或諸如痤瘡或牛皮癬之其他皮膚病症之活性成分,諸如角質溶解劑。由於在此等調配物中存在揮發性溶劑,在第一次使用之前或在使用期間自該週期性投與裝置之任何實質上溶劑洩露皆會造成治療組合物中所具有的活性成分濃度比目前規範當局所允許之濃度要高。
因此,存在一種對在封裝於週期性分配傳送系統中時維持組合物中可接受活性成分濃度之包含揮發性物質之化妝品或醫藥組合物之需求。此外,存在一種對當包含於週期性分配傳送系統中時在組合物中維持可接受活性成分濃度且提供充足的薄膜形成能力之薄膜形成醫藥組合物之需求。該組合物可更良好地避免揮發性溶劑過多量損失,該損失將會造成活性劑之濃度增加,從而超出該藥物產品管理允許範圍,但施用後仍可形成可用的治療薄膜。本發明提供之此等及其他觀點於文中及申請專利範圍中更加詳細地闡述及主張。
文中所引用之所有專利及非專利參考文獻之全文係以引用的方式併入本文中。此部份中任何參考文獻之鑑定或討論或此說明書之任何部份不應視為該參考文獻可作為本申請案之先前技術而獲得。
本發明提供一種用於局部施用之凝膠組合物,其包括高至約17%(w/w)濃度之水楊酸或其鹽、薄膜形成劑、及一或多種揮發性成分,其中該組合物包括約3%(w/w)至約14%(w/w)間之量的醚。
本發明進一步提供一種用於局部施用之凝膠組合物,其包括高至約17%(w/w)之濃度的水楊酸、約5至約20%(w/w)間的量之火棉膠產物及一或多種揮發性成分,其中該組合物包括約3%(w/w)至約14%(w/w)間之量的醚。
本發明亦提供一種用於局部施用之凝膠組合物,其包括高至約17%(w/w)濃度之水楊酸及以0.2至約1.0%(w/w)間之量的硝化纖維。
本發明進一步提供一種施用至皮膚之凝膠組合物,其包括角質溶解劑及包括約5%至20%(w/w)間的量之火棉膠產物及一或多種揮發性成分,其中該組合物包括約3%(w/w)至約14%(w/w)間的量之醚,其形成與皮膚充分接觸之薄膜以對角質溶解劑形成保護性屏障一段必需時間,從而對皮膚提供治療。
本發明亦提供一種施用至皮膚之凝膠組合物,其包括角質溶解劑及包括約0.2%至1.0%(w/w)間的量之硝化纖維及一或多種揮發性成分,其中該組合物包括約3%(w/w)至約14%(w/w)間的量之醚,其形成與皮膚充分接觸之薄膜以對角質溶解劑形成保護性屏障一段必需的時間,從而對皮膚提供治療。
本發明亦提供一種治療個體皮膚疾病之方法,其包括將本發明之組合物施用至皮膚上,其中該組合物形成與皮膚充分接觸之薄膜以對水楊酸形成保護性屏障一段必需的時間,從而對該損傷提供治療。
本發明進一步提供一種用於投與供治療個體皮膚疾病之組合物之分配器,其中該分配器包括含於與分配機構連通之儲存容器中之本發明之凝膠組合物及用於延遲該組合物中揮發性材料在施用至個體之前蒸發之機構。
如文中所述,本發明提供對包含活性成分及揮發性溶劑之組合物及儲存及傳送該組合物之傳送裝置之改良。在某些實施例中,該組合物亦含有薄膜形成劑。本發明之組合物提供在該組合物在該傳送裝置儲存及自其施用時揮發性成分之損失減少。在某些實施例中,該裝置包括經設計成易於施用調配物至皮膚以治療各種皮膚病症之筆型傳送系統。
調配物
在一個實施例中,本發明提供一種用於局部施用之液體組合物,其包括化妝品或醫藥上活性劑及其中該組合物包括約3%(w/w)至約14%(w/w)間的量之醚。在某些實施例中,該醚含量係約6%至約10%(w/w)之間。在某些實施例中,該醚含量係約6%至約7%(w/w)之間。在某些實施例中,該醚可包括可用於化妝品或醫藥組合物中之醚,特定言之二乙基醚。在某些實施例中,該組合物可包含其他揮發性醇成分,其包括可用於化妝品或醫藥組合物中之醇,諸如甲醇、乙醇及丙醇及其混合物。
在某些實施例中,本發明調配物係用於治療諸如疣、雞眼及胼胝之皮膚疾病。在其他實施例中,該調配物係用於治療其他疾病,諸如痤瘡、牛皮癬、皮膚乾燥、甲廯、腳趾甲內生及類似疾病。當經調配作為疣治療產品或雞眼及胼胝治療產品時,本發明某些實施例包含作為活性劑之水楊酸。當該組合物係意欲治療指甲之病症或疾病(即甲廯)時,可添加其他活性成分,諸如例如抗真菌劑,其包括克黴唑(clotrimazole)、布替那非(butenafine)、特比萘芬(terbinafine)、咪康唑(miconazole)。如文中所用,術語「水楊酸」包括對用於局部施用組合物可接受之酸及其任何鹽或酯。適宜的鹽包括其鈉、鉀、鈣、鋰或鎂鹽。適宜的酯包括其C1
至C4
酯,諸如水楊酸甲酯。其他酯包括雙水楊酸酯(水楊基水楊酸)、水楊酸之水楊酸酯。最佳使用酸形式作為活性成分。水楊酸亦稱為2-羥基苯甲酸。視需要而言,其他成分可用於局部製劑以幫助水楊酸滲入指甲及/或皮膚中。該試劑可包括指甲軟化劑及撕脫劑,諸如脲、巰基劑及以硫為主之還原劑,諸如硫化鈉、指甲滲透增強劑及堵塞劑及/或親水性填充劑以促進指甲及/或皮膚之水合作用。
USFDA專務法規規定在疣治療產品及雞眼/胼胝治療產品中活性成分濃度之限度,以在不需要進一步部門檢查下出售該產品。在該法規下,特別規定經所售組合物需列出水楊酸濃度。因此,在某些實施例中,該組合物可包含高至約17%(w/w)的量之水楊酸。在某些實施例中,該組合物可包含約5%至約17%間的量之水楊酸。然而,無論該調配物是否屬於某些醫藥或化妝品產品之管理內,本發明主旨之教示考慮一般技術者皆能製備之該調配物中更高含量的水楊酸。
在其他實施例中,本發明進一步包括用於局部施用之凝膠組合物,其包括水楊酸及包含約5至約20%(w/w)間的量之火棉膠產物。如文中所用,術語火棉膠產物包括火棉膠及可撓性火棉膠二者。火棉膠產物係經USP定義之調配物,其包括硝化纖維、二乙基醚及乙醇。硝化纖維發揮薄膜形成劑之作用,其保護活性成分(此處為水楊酸)在足以使活性成分影響治療之充足時間內不蒸發。可撓性火棉膠與火棉膠之區別在於添加樟腦及蓖麻油作為可塑劑。在某些實施例中,該組合物將包含約5%至約10%(w/w)間的量之火棉膠產物。因此,在某些實施例中,本發明提供一種用於施用至皮膚損傷之液體組合物,其包括水楊酸及包括約0.2%至1.0%(w/w)間的量之硝化纖維,其中該組合物形成與皮膚充分接觸之薄膜,以對水楊酸形成保護性屏障一段必需的時間,從而對該損傷提供治療。在某些實施例中,該組合物可包括約0.25%至約0.50%(w/w)間的量之硝化纖維。
在某些實施例中,本發明提供一種水楊酸調配物,其減少過去用於此等類型調配物中大部份揮發性溶劑之量,諸如乙醚,其具有沸點=34.5℃,然而仍然保持實際凝膠調配物能夠自週期性單位劑型分配器逐滴施用至需要其的個體之表面上。水楊酸自該裝置之施用將在皮膚上形成水楊酸傳送薄膜。在某些實施例中,本發明包括一種包含少量的低沸點溶劑(例如,具有低於40℃之沸點者,諸如乙醚)及包括較多量更高沸點溶劑(例如具有70℃以上之沸點者)之調配物,該較高沸點溶劑仍能溶解該薄膜形成聚合物且當施用至皮膚時產生良好的薄膜。該更高沸點溶劑之實例包括(例如)醋酸乙酯(沸點=77℃)及醋酸丁酯(沸點=118℃)。
在某些實施例中,本發明組合物進一步包括其他的增稠/增黏劑。例如,纖維素聚合物(諸如羥丙基纖維素),包括KlucelHF(Hercules Inc. Aqualon Division Hopewell,VA USA),可以添加高至約2.6%之量。在某些實施例中,本發明調配物進一步包括較少量之乳酸乙酯,其係對於硝化纖維及羥丙基纖維素二者之可塑劑,從而以改善藉由該調配物所施用、乾燥的薄膜之強度/可撓性之量存在。
在某些實施例中,本發明之調配物包含以改善所施加、乾燥之薄膜之強度/可撓性之量的額外硝化纖維。例如,如上所提及,該調配物包含來自含於較高沸點溶劑(諸如醋酸乙酯或其他醋酸烷酯)中之焦木素溶液之硝化纖維。該焦木素溶液係購得(CAS 9004-70-0)(Alfa Chem,Kings Point,NY USA)及已用於化妝品應用(諸如指甲油)及傢具用漆中。在某些實施例中,本發明包括可與硝化纖維相容之聚合物以改善薄膜形成特性,例如Gantrez聚合物材料,諸如由ISP International Specialty Products(Wayne,NJ,USA)生產之Gantrez ES-425、Gantrez ES 335-I、及Gantrez ES-225。此等Gantrez聚合物係聚甲基乙烯基醚/馬來酸(PVM/MA)之烷基酯,其包括PVM/MA之丁基、異丙基及乙基酯。彼等一般技術者應瞭解適宜的PVM/MA聚合物將呈現與所建議之調配物中其他聚合物薄膜形成劑/增劑黏之相容性,以在應用時形成良好的品質、牢固、可撓性薄膜。
在某些實施例中,本發明之組合物可包括含於用於傳統疣治療之化合物中之局部麻醉劑,本發明可緩解通常將角質溶解劑施用至皮膚之相關之局部不適及刺激。局部麻醉劑包括(但不限於)苯甲酸之酯,諸如苯唑卡因(benzocaine)、普魯卡因(procaine)、丁卡因(tetracaine)及氯普魯卡因(chloroprocaine);及醯胺類,諸如丁哌卡因(bupivacaine)、辛可卡因(dibucaine)、利多卡因(lidocaine)、馬比氟卡因(mepivacaine)、丙胺卡因(prilocaine)及依替卡因(etidocaine)。所存在之局部麻醉劑之量可在該組合物所施加之區域中有效地達到局部化麻醉,一般基於該組合物之重量為約0.5重量%至約15重量%或更多及較佳為1重量%至10重量%。對於利多卡因,例如,有效範圍為約0.5%至約4%。就苯唑卡因而言,有效範圍係約5%至約25%。
治療方法
本發明進一步包括使用本發明之低醚含量組合物治療各種皮膚疾病之方法。因此,在某些實施例中,本發明提供一種治療個體疾病之方法,其包括施用包括角質溶解劑及以約0.2至1.0%(w/w)間的量之硝化纖維之組合物至個體之罹患區域,其中該組合物形成與皮膚充分接觸之薄膜以對該角質溶解劑形成保護性屏障一段必需的時間,從而對該罹患區域提供治療。如下文所證實,本發明之以低醚含量調配之凝膠組合物令人驚訝地提供比先前組合物更優異之薄膜。因此,據信由於活性劑自改良的薄膜之放大暴露之效益,該組合物提供在治療可容易地用該等組合物治療之疾病中之進展。在某些實施例中,該角質溶解劑可為水楊酸、抗壞血酸、泛酸鈣、冰醋酸、乳酸、鬼臼樹脂及氯化鋅或其組合物。在某些實施例中,水楊酸係以高至約17%之量存在。在某些實施例中,水楊酸係以約5%(w/w)至17%(w/w)間的量存在。在某些實施例中,該疾病可包括皮膚疾病,諸如疣、雞眼及胼胝。在其他實施例中,該疾病包括痤瘡、牛皮癬、皮膚乾燥、甲廯或腳趾甲內生。
角質溶解劑一般係用於局部治療角化過度及藉由軟化及消除皮膚之角質層而發揮作用,藉此增強施用位點之脫落。因此,在一態樣中,本發明可使用本發明之薄膜形成流體組合物用以治療角化過度,該組合物包括角質溶解劑(諸如水楊酸)、可撓性火棉膠及以足以增加所形成薄膜之彈力之量的局部可接受聚合物,其可表現改良的順服性及改良的治療效力。
本發明亦包括治療疣之方法,其包括施用一組合物至疣,該組合物包括治療上有效量之至少一種本發明之組合物。在某些實施例中,該方法包括施用包括水楊酸或其鹽之本發明之組合物。一般而言,該組合物可每天或間歇性地間隔施用至疣,諸如每週二或三次。治療的時間可根據疣之大小而大不相同。
本發明進一步包括治療甲廯之方法,其包括施用一組合物至指甲,該組合物包括治療上有效量的至少一種本發明之組合物。一般而言,該製劑可每日或間歇性間隔施用至指甲,諸如每週二或三次。治療的時間可根據感染的嚴重程度、欲治療指甲之身體部份、患者年齡、指甲厚度、指甲生長速度及類似因素而大不相同。一般而言,一般預期較年幼患者之腳趾甲應接受長達6個月的治療,然而預期較年長患者之腳趾甲應接受長達約一年的治療。此等時間反映腳趾甲完全長出腳趾外所需之時間。預期手指甲之治療更快,因為手指甲生長大約係腳趾甲生長的兩倍。治療的效率可藉由症狀的減少或消失來評估。較不嚴重的情況,即僅有指甲的末梢部份感染則預期需要治療的時間更短。
裝置
本發明進一步提供一種如文中所述之用於投與供治療皮膚病症之組合物之分配器,其中該分配器包括含於與分配機構連通之儲存容器中之本發明之液體組合物及用於延遲該組合物中揮發性材料在施用至個體之前的蒸發之機構。在本發明之某些實施例中,該分配器係呈筆狀裝置之形式。
在某些實施例中,該分配器包括延遲該組合物之揮發性成分蒸發之額外裝置,諸如自屏障薄膜製造之囊袋及其係在將分配器置於其內部之後密封。在其他實施例中,用於延遲揮發性材料蒸發的裝置係將密封機構置於儲存容器與分配裝置之間。
在某些實施例中,本發明提供一種藉由將該調配物自包括容納水楊酸調配物之儲存容器之裝置施用而將包含水楊酸之調配物施用至需要該治療之個體之裝置,一種用於將調配物自儲存容器連通至個體之表面(諸如皮膚或指甲或頭髮表面)之分配噴嘴,及用於迫使該調配物通過該分配噴嘴之壓力機構。該壓力機構可為藉由使用者機械地操作之活塞或迫使調配物通過分配噴嘴之開口之類似機構。本發明亦提供一種經設計用於延遲揮發性溶劑成分離開筆分配器系統之演變之分配裝置。在某些實施例中,該分配裝置包括具有包含水楊酸之桶形儲存容器之筆型分配器、將調配物保持於儲存容器中直至該儲存容器上之壓力引起調配物移動經過該分配噴嘴中之屏障及形成待施用至需要該治療的個體之表面上之小液滴之分配噴嘴。例如,可使用藉由個體驅動之活塞而施加壓力。該裝置可視需要包含在不使用時將分配器封閉起來之蓋帽。本發明所提供之改良包括筆本身之設計元素,其包括密封劑機構之構造之類型及材料。在某些先前技術裝置中,密封劑裝置係位於與該裝置之分配噴嘴末端相反之筆分配器之活塞末端的「O」形環。在某些實施例中,本發明包括使該裝置在分配器末端裝備有複數個自適宜的、耐溶劑型材料製成之橡膠「O」形環型或等效的密封劑裝置,以封鎖揮發性調配物成分自經填充之裝置之任何演變。此外,本發明之裝置可包括一或多種溶劑屏障薄膜黏著帶,例如(諸如)購自3M(St. Paul,MN,USA)之9792R鋁帶,以密封該等筆中之接縫,諸如覆蓋筆分配器之蓋帽與經調配物填充之筆管之間。在某些實施例中,本發明之裝置進一步包括將該裝置與以上所提及之調配物改質劑、密封劑、膠帶組合或單獨進行二級包裝,其係(例如)藉由將經填充之分配器裝置置於自熱可密封、分層封裝之薄膜製成之囊袋中,諸如PET/鋁箔/黏著劑材料,諸如彼等購自Hueck Foils(例如TPMSF005SB)(Wall,NJ,USA)者。
試驗
表1顯示包含17% w/w水楊酸之試驗凝膠調配物,其係用兩種已知的水楊酸調配物製備及比較以測定其經受筆狀分配器裝置中之揮發性物質蒸發之能力。該凝膠對照調配物相較於液體對照及所添加之醇而言,包含較少量的火棉膠,及因此包含較低醚含量。相較於凝膠對照調配物而言,該實驗凝膠調配物係經設計具有較低量的火棉膠,以進一步降低揮發性成分及減少溶劑之蒸發,然而一旦施用至皮膚仍然產生可見薄膜。表中所有量係以該調配物之重量百分比列出。可撓性或火棉膠重量量係基於可撓性火棉膠組分(焦木素(硝化纖維)、蓖麻油、樟腦、乙醇、及乙基醚)之重量百分比而列出。
所有調配物係在缸中使用壓縮空氣操作混合電動機、雙刃混合軸而製備。石蠟膜係用於在混合操作期間覆蓋缸之開口。醇、乳酸乙酯及Indopol L-50首先係裝入該缸中及混合10分鐘。隨後將水楊酸添加至該混合物中及混合30分鐘。繼而,將可撓性火棉膠添加至該混合物中及混合10分鐘。隨後將Klucel HF粉末緩慢添加至該混合物中,同時混合約3至5分鐘的時間及將最終混合物進一步混合30分鐘以完成該混合。
選擇實例調配物3及4以與凝膠對照調配物進一步分析比較,以測定調配物當儲存於筆狀分配器裝置中時,對揮發性物質在室溫下及在40℃下經時蒸發之作用。將調配物裝入60 c.c.注入器中,其係用於將凝膠溶液填充至筆管中。將筆管以塑料插入件密封、用矽酮覆蓋噴嘴管及用該蓋帽扣合。將筆樣品在室溫下及在40℃下老化13週。圖1顯示測試結果,其顯示本發明之調配物提供在減少揮發性成分在室溫及高溫條件下經時損失之實質上改良。
將實例凝膠調配物3與液體對照調配物相比較,進一步經受活體外薄膜形成測試。圖2係將兩滴對照液體調配物用滴管置於玻璃顯微鏡載片上,及隨後乾燥若干分鐘直至完全乾燥之顯微鏡照片。該數字顯微鏡影像係以放大20X完成。顯微鏡照片上之標記顯示玻璃載片上之乾燥薄膜直徑係約7.5 mm。圖3係將兩滴對照液體調配物用滴管置於玻璃顯微鏡載片上,及隨後乾燥若干分鐘直至完全乾燥之顯微鏡照片。該影像係使用相同的顯微鏡放大30X而產生。顯微鏡照片上之標記顯示乾燥薄膜點直徑係約4 mm。圖4係將兩滴實例凝膠調配物3用滴管置於玻璃顯微鏡載片上,及隨後乾燥若干分鐘直至完全乾燥之顯微鏡照片。該影像係使用相同的顯微鏡放大20X而產生。顯微鏡照片上之標記顯示乾燥薄膜點直徑係約8.1 mm。
圖2(液體對照)、圖3(凝膠對照)及圖4(實例調配物3)之比較顯示藉由本發明之實例調配物所證明之薄膜形成中的出乎意料的益處。來自液體對照及凝膠調配物之乾燥薄膜點首先係在圍繞該等小液滴之外部周圍乾燥,從而造成該區域相當厚、「山脈狀」薄膜。由於此,存在位於在山脈狀內部區域之載片上之實質上較少的材料及該薄膜厚度在該區域中並不均一。該對照薄膜亦證明許多小微米大小亞微粒及亞微粒團塊之聚集結構。相反地,來自實例凝膠調配物3之乾燥薄膜均勻地自其整個表面乾燥,並非自邊緣,及然而可見較小微粒之某些更大的聚集物,總而言之其在其整個區域中更加密集及更均勻。
圖1係闡述將經對照物及本發明凝膠調配物填充之筆在室溫(RT)及高溫(40℃)下保持13週時之平均重量百分比損失之圖。
圖2係顯示藉由液體對照調配物所形成之薄膜之放大20X的顯微鏡照片。
圖3係顯示藉由凝膠對照調配物所形成之薄膜之放大30X的顯微鏡照片。
圖4係顯示藉由本發明凝膠調配物所形成之薄膜之放大20X的顯微鏡照片。
(無元件符號說明)
Claims (9)
- 一種局部施用之凝膠組合物,其包括約17%(w/w)濃度之水楊酸、含量介於約5至約10%(w/w)間之可撓性火棉膠產物,及含量介於約20至約25%(w/w)間之乳酸乙酯,其中該可撓性火棉膠產物包含約65.8%(w/w)之二乙醚,約24.3%(w/w)之乙醇,約2%(w/w)之樟腦,約3%(w/w)之蓖麻油及約4.9%(w/w)之硝化纖維。
- 一種疣治療產品,其包括請求項1之組合物。
- 一種雞眼/胼胝治療產品,其包括請求項1之組合物。
- 如請求項1之凝膠組合物,其進一步包括麻醉劑。
- 一種請求項1之凝膠組合物於製備用於治療個體皮膚疾病之藥劑之用途,其中該組合物形成與皮膚充分接觸之薄膜以對水楊酸形成屏障一段必需時間,從而對病灶提供治療。
- 一種用於投與組合物以治療個體皮膚疾病之分配器,其中該分配器包括含於與分配機構連通之儲存容器中之如請求項1之凝膠組合物及用於延遲該組合物中揮發性材料在施用至個體之前蒸發之機構。
- 如請求項6之分配器,其係呈筆狀裝置之形式。
- 如請求項6之分配器,其中該用於延遲易揮發性材料蒸發之機構係一囊袋,其在將分配器置於內部之後即經密封。
- 如請求項8之分配器,其中該囊袋包括屏障薄膜。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24978809P | 2009-10-08 | 2009-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201125567A TW201125567A (en) | 2011-08-01 |
TWI488628B true TWI488628B (zh) | 2015-06-21 |
Family
ID=43855046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099134249A TWI488628B (zh) | 2009-10-08 | 2010-10-07 | 水楊酸藥物之組合物及裝置 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8883767B2 (zh) |
EP (1) | EP2485720B1 (zh) |
JP (4) | JP5798561B2 (zh) |
KR (1) | KR101791705B1 (zh) |
CN (2) | CN107411990A (zh) |
AR (2) | AR078553A1 (zh) |
AU (1) | AU2010303696B2 (zh) |
BR (1) | BR112012007550B1 (zh) |
CA (1) | CA2775089C (zh) |
ES (1) | ES2688976T3 (zh) |
HK (1) | HK1247133A1 (zh) |
IN (1) | IN2012DN02817A (zh) |
MX (1) | MX2012004144A (zh) |
RU (1) | RU2552470C2 (zh) |
TW (1) | TWI488628B (zh) |
WO (1) | WO2011044008A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007012041A2 (en) | 2005-07-20 | 2007-01-25 | Lab Partners Associates, Inc. | Wireless photographic communication system and method |
US7783188B2 (en) | 2007-05-29 | 2010-08-24 | Lab Partners Associates, Inc. | System and method for maintaining hot shoe communications between a camera and a wireless device |
JP6308137B2 (ja) * | 2012-12-28 | 2018-04-11 | 大正製薬株式会社 | 皮膚適用製剤 |
JP2014234377A (ja) * | 2013-06-04 | 2014-12-15 | ニチバン株式会社 | サリチル酸含有製剤、及び、その製造方法 |
KR20230129619A (ko) * | 2013-08-21 | 2023-09-08 | 베리카 파마슈티컬스 인크. | 피부 질병의 치료를 위한 조성물, 방법 및 시스템 |
WO2016100732A2 (en) | 2014-12-17 | 2016-06-23 | Verrica Pharmaceuticals, Inc. | Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives |
US11168091B2 (en) | 2015-01-20 | 2021-11-09 | Verrica Pharmaceuticals Inc. | Quantification and preparation of pharmaceutical grade cantharidin |
EP3258908A4 (en) | 2015-02-20 | 2018-08-22 | Pedicis Research LLC | Compositions and methods for treatment of skin infections |
ES2620319B1 (es) * | 2015-12-28 | 2018-05-04 | Laboratorios Viñas S.A. | Composición farmacéutica para uso tópico de ácido salicílico para tratamiento de la hiperqueratosis y método correspondiente |
JP6775976B2 (ja) * | 2016-03-18 | 2020-10-28 | 小林製薬株式会社 | 皮膚摩擦軽減用外用製剤 |
ITUA20162327A1 (it) * | 2016-04-05 | 2017-10-05 | Sixtem Life Srl | Prodotto per il trattamento di lesioni della pelle e di verruche e dispositivo applicatore |
US11147790B2 (en) | 2017-06-06 | 2021-10-19 | Verrica Pharmaceuticals Inc. | Treatment of cutaneous disorders |
WO2018232277A1 (en) * | 2017-06-15 | 2018-12-20 | Verrica Pharmaceuticals, Inc. | Devices and methods for the treatment of body surface disorders |
USD900312S1 (en) | 2017-06-15 | 2020-10-27 | Verrica Pharmaceuticals, Inc. | Applicator |
JP7048221B2 (ja) * | 2017-06-26 | 2022-04-05 | 小林製薬株式会社 | 皮膜形成性外用製剤 |
JP6968589B2 (ja) * | 2017-06-26 | 2021-11-17 | 小林製薬株式会社 | 皮膜形成性外用製剤 |
WO2019025884A1 (en) * | 2017-08-04 | 2019-02-07 | Poli Md S.R.L. | MEDICAL DEVICE FOR THE TREATMENT OF PVH SKIN INFECTIONS |
KR102648939B1 (ko) * | 2023-08-18 | 2024-03-19 | 한국콜마주식회사 | 산을 고함량으로 함유하는 화장료 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525358A (en) * | 1990-05-07 | 1996-06-11 | Schering-Plough Healthcare Products, Inc. | Gel film-forming flexible collodion compositions |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4149814A (en) * | 1977-06-20 | 1979-04-17 | E. I. Du Pont De Nemours And Company | Fountain brush liquid applicator |
US4783185A (en) * | 1986-07-07 | 1988-11-08 | Minnesota Mining And Manufacturing Company | Pen-like dispenser for applying rust converting liquid |
JPH02311414A (ja) * | 1989-05-29 | 1990-12-27 | Shiseido Co Ltd | 皮膚外用剤 |
CA2101083C (en) * | 1991-02-01 | 2004-09-14 | Karl F. Popp | Improved flexible collodion compositions |
JP3117502B2 (ja) * | 1991-08-27 | 2000-12-18 | 株式会社資生堂 | 皮膚外用剤 |
RU2114607C1 (ru) * | 1997-06-24 | 1998-07-10 | Закрытое акционерное общество "Садко" | Лечебно-гигиеническое и косметическое средство "троя" для ухода за кожей |
JP4177738B2 (ja) | 2003-09-18 | 2008-11-05 | 株式会社トキワ | 塗布具 |
EP1750540A1 (en) * | 2004-05-22 | 2007-02-14 | Ball Burnishing Machine Tools Limited | Multi-function surface treatment tool |
GB0411467D0 (en) * | 2004-05-22 | 2004-06-23 | Ball Burnishing Mach Tools | A tapered applicator for treating and cleaning surfaces |
US7201527B2 (en) | 2004-07-30 | 2007-04-10 | Hct Limited | Twist up pen type dispenser with brush applicator |
US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
FR2878157B1 (fr) * | 2004-11-23 | 2007-03-02 | Durlin France Sa | Composition de vernis a base de solvant a base de solvant d'origine vegetale |
JP4863437B2 (ja) * | 2005-07-07 | 2012-01-25 | 有限会社日本健康科学研究センター | 浴用フィルム製剤 |
US20070048355A1 (en) * | 2005-08-26 | 2007-03-01 | Daniel Perlman | Non-irritating solvent-borne polymeric coatings for application to the skin |
JP5010125B2 (ja) * | 2005-09-02 | 2012-08-29 | 有限会社日本健康科学研究センター | 水虫治療用フィルム製剤 |
WO2008050491A1 (fr) * | 2006-10-24 | 2008-05-02 | Japan Health Science Research Center.Ltd. | Préparation de film servant à former un film sur la peau |
US20080312196A1 (en) * | 2007-06-15 | 2008-12-18 | Cohen Carl J | Topical wart removal composition |
EP2143421A1 (en) * | 2008-07-07 | 2010-01-13 | Almirall Hermal GmbH | Topical composition for the treatment of actinic keratosis |
CN102089024B (zh) * | 2008-07-09 | 2014-06-25 | 赛诺菲-安万特德国有限公司 | 药物递送装置和组装药物递送装置的方法 |
JP6062186B2 (ja) * | 2012-08-28 | 2017-01-18 | 古河電気工業株式会社 | 分岐鉄塔の架空線工事方法 |
-
2010
- 2010-10-04 US US12/897,476 patent/US8883767B2/en not_active Expired - Fee Related
- 2010-10-04 ES ES10822460.1T patent/ES2688976T3/es active Active
- 2010-10-04 MX MX2012004144A patent/MX2012004144A/es active IP Right Grant
- 2010-10-04 IN IN2817DEN2012 patent/IN2012DN02817A/en unknown
- 2010-10-04 BR BR112012007550A patent/BR112012007550B1/pt not_active IP Right Cessation
- 2010-10-04 RU RU2012118757/15A patent/RU2552470C2/ru not_active IP Right Cessation
- 2010-10-04 EP EP10822460.1A patent/EP2485720B1/en not_active Not-in-force
- 2010-10-04 WO PCT/US2010/051257 patent/WO2011044008A1/en active Application Filing
- 2010-10-04 JP JP2012533227A patent/JP5798561B2/ja not_active Expired - Fee Related
- 2010-10-04 CN CN201611175958.XA patent/CN107411990A/zh active Pending
- 2010-10-04 AU AU2010303696A patent/AU2010303696B2/en not_active Ceased
- 2010-10-04 CN CN2010800447918A patent/CN102573816A/zh active Pending
- 2010-10-04 KR KR1020127008997A patent/KR101791705B1/ko active IP Right Grant
- 2010-10-04 CA CA2775089A patent/CA2775089C/en not_active Expired - Fee Related
- 2010-10-07 AR ARP100103651A patent/AR078553A1/es active IP Right Grant
- 2010-10-07 TW TW099134249A patent/TWI488628B/zh not_active IP Right Cessation
-
2014
- 2014-03-07 JP JP2014045597A patent/JP6317958B2/ja active Active
-
2015
- 2015-07-03 JP JP2015134371A patent/JP2016000732A/ja active Pending
-
2016
- 2016-04-21 JP JP2016084980A patent/JP6200546B2/ja not_active Expired - Fee Related
-
2017
- 2017-08-11 AR ARP170102247A patent/AR109324A2/es active IP Right Grant
-
2018
- 2018-05-28 HK HK18106914.0A patent/HK1247133A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525358A (en) * | 1990-05-07 | 1996-06-11 | Schering-Plough Healthcare Products, Inc. | Gel film-forming flexible collodion compositions |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI488628B (zh) | 水楊酸藥物之組合物及裝置 | |
CA2931144C (en) | Anti-infective methods, compositions, and devices | |
CN1048979A (zh) | 在人体组织上原位成膜的制剂和方法 | |
ES2391409T3 (es) | Composición antifúngica | |
JP2018177724A (ja) | 外用薬 | |
JP2010502647A (ja) | 義歯ケア用組成物 | |
CN113347982A (zh) | 真皮皮肤保护剂和载体 | |
BRPI0717493A2 (pt) | Fungicida subungueal e método para tratar onicomicoses | |
TW202239430A (zh) | 外用劑組合物 | |
JP7475468B2 (ja) | 皮膜形成エアゾール組成物及びエアゾール型皮膜形成外用製剤 | |
AU2009206283A1 (en) | Acetic acid/thymol compositions and their use in the treatment of onychomycosis | |
WO2023009829A1 (en) | Topical formulations containing erythritol and methods of treating skin conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |